Intellia, San Raffaele Partner on CRISPR/Cas9-Edited Anticancer T-Cell Therapies – Genetic Engineering & Biotechnology News
|
Intellia, San Raffaele Partner on CRISPR/Cas9-Edited Anticancer T-Cell Therapies
Genetic Engineering & Biotechnology News The 3-year research collaboration, option, and license agreement will aim to leverage Intellia's CRISPR/Cas9 genome-editing platform to generate improved T-cell therapies for both hematologic and solid tumors. The agreement includes options and … Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing … Latest Stocks: Zacks: Crispr Therapeutics AG (CRSP) Receives Consensus Rating of “Strong Buy” from Analysts BRIEF-Intellia Therapeutics and San Raffaele University and Research Hospital to combine CRISPR/cas9 genome … |
